Teva Presents First Real-World Evidence Demonstrating Treatment with DuoResp Spiromax® Inhaler was Comparable to Symbicort Turbuhaler®
Amsterdam (ots/PRNewswire) - ONLY FOR PAN-EUROPEAN/ EUROPEAN ENGLISH LANGUAGE MEDICAL TRADE MEDIA Study Highlights Improved Outcomes for Asthma Patients Including Fewer Exacerbations Following Change in Treatment to DuoResp Spiromax® Teva Pharmaceuticals Europe B.V., (NYSE and TASE: TEVA) today announced data from ...